Calidi Biotherapeutics to Present RedTail Platform at H.C. Wainwright Global Investment Conference

Calidi Biotherapeutics Inc. (NYSE American: CLDI) announced that CEO Eric Poma, Ph.D., will present at the H.C. Wainwright 27th Annual Global Investment Conference scheduled for September 8-10, 2025, at the Lotte New York Palace Hotel in New York. An on-demand presentation will be available starting September 5 at 7 a.m. ET, providing investors and stakeholders with detailed insights into the company's groundbreaking RedTail platform technology.

The presentation holds significant importance as it showcases Calidi's proprietary RedTail platform, which represents a major advancement in immuno-oncology therapeutics. This engineered enveloped oncolytic virus platform is specifically designed to protect the virus from immune clearance, induce tumor lysis, and deliver therapeutic genetic medicines to metastatic sites through systemic administration. The ability to systemically deliver targeted therapies to distal disease sites addresses a critical unmet need in cancer treatment, particularly for metastatic cancers that have traditionally been difficult to treat effectively.

Calidi Biotherapeutics is a clinical-stage immuno-oncology company pioneering the development of targeted therapies with the potential to transform cancer treatment paradigms. The company's latest news and updates are available in their newsroom at https://ibn.fm/CLDI. The RedTail platform's lead candidate, currently in IND-enabling studies, targets non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical need, representing a substantial market opportunity and potential breakthrough in oncology therapeutics.

The participation in this prestigious investment conference provides Calidi with a platform to demonstrate the clinical and commercial potential of their technology to a global audience of investors, analysts, and industry experts. The timing of this presentation is particularly strategic as the company advances its clinical programs and seeks to build momentum for its innovative approach to cancer treatment. The availability of an on-demand presentation starting September 5 ensures broader accessibility and allows for comprehensive review of the technology's capabilities and progress.

This presentation matters because it highlights the convergence of advanced biotechnology and cancer treatment, potentially offering new hope for patients with metastatic cancers. The RedTail platform's ability to systemically deliver genetic medicines to distant tumor sites could represent a paradigm shift in how metastatic cancer is treated, moving beyond traditional localized therapies to comprehensive systemic approaches. The investment community's interest in such innovative technologies underscores the growing recognition of the transformative potential of advanced biotherapeutics in addressing some of medicine's most challenging conditions.